Marie-sarah S. Dilhuydy

Pessac-sur-dordogne, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.

Journal: Cancer

Published: November 15, 2025

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Journal: EClinicalMedicine

Published: July 30, 2025

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.

Journal: Annals of hematology

Published: December 26, 2023

Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.

Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.

Journal: Annales de biologie clinique

Published: October 21, 2023

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.

Journal: Blood advances

Published: December 20, 2022

Elevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansion.

Elevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansion.

Journal: Journal of leukocyte biology

Published: April 15, 2022

eBEACOPP or A-AVD in advanced Hodgkin lymphoma: (re)thinking the toxicities in the PET-driven strategies era.

eBEACOPP or A-AVD in advanced Hodgkin lymphoma: (re)thinking the toxicities in the PET-driven strategies era.

Journal: The Lancet. Haematology

Published: July 27, 2021

Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).

Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).

Journal: American journal of hematology

Published: June 02, 2021

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Journal: Leukemia & lymphoma

Published: August 09, 2020

Vinblastine for elderly and frail patients with Hodgkin lymphoma.

Vinblastine for elderly and frail patients with Hodgkin lymphoma.

Journal: Leukemia & lymphoma

Published: July 28, 2020

Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.

Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.

Journal: Annals of hematology

Published: July 15, 2020

A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.

A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.

Journal: Blood

Published: July 13, 2020

Showing 1-12 of 39

Last Updated: 09/26/2026